Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AVTX

AVTX - Avalo Therapeutics, Inc. Stock Price, Fair Value and News

4.44USD-0.23 (-4.93%)Market Closed
Watchlist

Market Summary

USD4.44-0.23
Market Closed
-4.93%

AVTX Alerts

  • Point72 Asset Management, L.P. reported owning 0.3% of AVTX [2024-02-14]

AVTX Stock Price

View Fullscreen

AVTX RSI Chart

AVTX Valuation

Market Cap

854.2M

Price/Earnings (Trailing)

-25.74

Price/Sales (Trailing)

51.26

EV/EBITDA

-0.25

Price/Free Cashflow

-26.79

AVTX Price/Sales (Trailing)

AVTX Profitability

Return on Equity

-225.85%

Return on Assets

-113.39%

Free Cashflow Yield

-3.73%

AVTX Fundamentals

AVTX Revenue

Revenue (TTM)

18.1M

Rev. Growth (Yr)

-98.42%

Rev. Growth (Qtr)

-63.3%

AVTX Earnings

Earnings (TTM)

-33.2M

Earnings Growth (Yr)

-263.78%

Earnings Growth (Qtr)

36.19%

Breaking Down AVTX Revenue

Last 7 days

-4.7%

Last 30 days

-22.0%

Last 90 days

4855.6%

Trailing 12 Months

42.0%

How does AVTX drawdown profile look like?

AVTX Financial Health

Current Ratio

2.11

Debt/Equity

0.97

Debt/Cashflow

-2.24

AVTX Investor Care

Shares Dilution (1Y)

1943.56%

Diluted EPS (TTM)

-2.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20226.1M3.8M17.4M18.1M
20214.4M6.4M6.7M5.4M
20206.9M6.9M5.8M6.7M
20197.0M6.9M6.8M6.8M
201832.2M36.5M15.6M7.0M
20171.5M10.3M19.1M27.8M
20160001.2M

Tracking the Latest Insider Buys and Sells of Avalo Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 27, 2023
armistice capital, llc
sold
-486,888
0.5194
-937,404
-
Jun 26, 2023
caissa capital management ltd.
bought
-113,026
0.62
-182,300
-
Jun 26, 2023
armistice capital, llc
sold
-1,682,010
0.6125
-2,746,140
-
Jun 26, 2023
caissa capital management ltd.
bought
-917,153
0.6433
-1,425,700
-
Jun 20, 2023
caissa capital management ltd.
bought
8,288
4.1444
2,000
-
Jun 16, 2023
caissa capital management ltd.
bought
11,714
3.9048
3,000
-
Jun 15, 2023
caissa capital management ltd.
bought
11,640
3.6837
3,160
-
Jun 14, 2023
caissa capital management ltd.
bought
20,874
3.479
6,000
-
Jun 13, 2023
caissa capital management ltd.
bought
33,439
3.8216
8,750
-
Jun 12, 2023
caissa capital management ltd.
bought
9,316
4.3352
2,149
-

1–10 of 50

Which funds bought or sold AVTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-22,000
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
sold off
-100
-3,317
-
-%
Feb 14, 2024
Royal Bank of Canada
new
-
1,000
1,000
-%
Feb 14, 2024
Royal Bank of Canada
sold off
-100
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
sold off
-100
-11,082
-
-%
Feb 14, 2024
Mariner, LLC
sold off
-100
-2,243
-
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-1,883
-
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
new
-
18.00
18.00
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
sold off
-100
-21.00
-
-%

1–10 of 47

Are Funds Buying or Selling AVTX?

Are funds buying AVTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVTX
No. of Funds

Unveiling Avalo Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
0.0%
0
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
0.3%
2,500
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
4.9%
42,100
SC 13G/A
Feb 14, 2024
great point partners llc
0.26%
2,085
SC 13G/A
Jun 29, 2023
caissa capital management ltd.
0%
0
SC 13G/A
Jun 28, 2023
armistice capital, llc
4.7%
588,850
SC 13D/A
Apr 19, 2023
caissa capital management ltd.
9.81%
1,292,700
SC 13G/A
Feb 17, 2023
venrock healthcare capital partners iii, l.p.
9.99%
1,352,285
SC 13G
Feb 14, 2023
caissa capital management ltd.
9.19%
1,211,371
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
5.3%
500,737
SC 13G/A

Recent SEC filings of Avalo Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Jan 31, 2024
8-K
Current Report
Dec 28, 2023
8-K
Current Report
Dec 21, 2023
4
Insider Trading
Dec 21, 2023
4
Insider Trading
Dec 21, 2023
4
Insider Trading
Dec 21, 2023
4
Insider Trading

Peers (Alternatives to Avalo Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
3.9B
631.9M
-12.60% 32.37%
-26.2
6.17
23.54% 31.53%
SMALL-CAP
1.6B
348.4M
-3.38% -9.50%
25.02
4.46
81.69% -7.29%
521.5M
1.0B
-9.17% -57.89%
-0.95
0.5
-43.15% 58.48%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Avalo Therapeutics, Inc. News

Latest updates
Yahoo Finance26 Feb 202404:28 pm
InvestorsObserver02 Jan 202408:00 am

Avalo Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-63.3%236,000643,000769,500896,00014,949,0001,033,0001,173,000219,5001,350,0003,355,000473,0001,496,5001,111,0001,338,0002,754,000568,9932,201,2321,391,9422,600,0003,337,5004,075,000
Costs and Expenses-48.9%3,986,0007,793,0009,267,0009,750,50010,854,00012,861,00022,026,00018,182,00017,813,00020,484,00031,053,00017,835,00014,388,00013,153,00034,167,0006,303,6435,062,7953,940,0117,581,311--
Operating Expenses-----------------9,328,63210,425,25012,434,21510,477,38428,388,101
  S&GA Expenses2.6%2,490,0002,427,0002,708,0002,959,0003,284,0002,784,00011,684,0008,437,0005,926,0007,404,000435,000549,000462,000653,000677,000547,701214,207325,861396,276-5,338,1462,310,760
  R&D Expenses-------------------3,401,189--
EBITDA Margin----1.29--2.24-17.46-11.83-15.55-12.66-12.39-16.81-9.85-11.26-7.34-5.08-1.31-0.74----
Interest Expenses-33.9%486,000735,000704,000675,000599,000826,000831,000789,000796,000------262,500262,500262,500262,500262,500262,500
Income Taxes14.3%8,0007,0008,0008,5005,0005,0009,000-16,0008,000-199,00011,000-185,5003,000-454,000-2,157,0003,593100,00053,446100,000-141,54252,412
Earnings Before Taxes36.2%-5,220,000-8,186,000-9,947,000-3,197,000-12,982,000-22,042,000--17,463,000-17,373,000-30,563,000--13,258,000-13,280,000-24,312,000--2,808,852-2,490,747-5,031,702--
EBT Margin----1.46--2.44-18.54-12.44-16.15-13.06-12.68-17.23-10.12-11.63-7.78-5.66-2.04-1.23----
Net Income36.2%-5,228,000-8,193,000-9,955,000-9,812,0003,192,000-12,987,000-22,051,000-19,196,000-17,395,000-17,105,000-30,680,000-15,643,000-13,459,000-13,281,000-21,117,0001,621,054-4,016,454-6,223,099-7,454,048-5,558,913-24,603,575
Net Income Margin-34.0%-1.84-1.37-1.64-2.31-2.94-18.97-12.42-15.63-12.11-11.95-16.54-9.48---------
Free Cashflow38.5%-6,800,000-11,048,000-10,052,000-3,989,0005,687,000-12,526,000-16,067,000-17,110,000-16,371,000-19,187,000-18,337,000-14,375,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets20.8%29.0024.0036.0033.0037.0032.0062.0080.0095.0064.0063.0044.0059.0069.0044.0036.0057.0060.0075.0070.0068.00
  Current Assets68.4%13.008.0019.0016.0019.0015.0044.0062.0077.0047.0046.0026.0041.0050.0025.0018.0013.0014.0027.0022.0018.00
    Cash Equivalents61.4%10.006.0017.0013.0017.0011.0038.0055.0072.0040.0038.0019.0033.0045.006.004.005.009.0016.0011.007.00
  Inventory-100.0%-0.000.000.000.000.000.000.000.000.00-0.000.000.000.000.000.001.001.000.001.00
  Net PPE-------------2.002.001.001.001.002.001.001.000.00
  Goodwill0%14.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0016.0016.0016.0014.0016.00
Liabilities-53.3%15.0031.0043.0044.0039.0038.0056.0057.0055.0042.0030.0019.0021.0019.0019.0015.0039.0042.0052.0049.0048.00
  Current Liabilities-73.3%6.0022.0023.0022.0018.0015.0018.0020.0019.0022.0026.0015.0017.0015.0015.0012.0017.0019.0028.0026.0025.00
  Long Term Debt-----------------14.0014.0014.0014.0014.00
    LT Debt, Current-----------------1.001.001.001.001.00
    LT Debt, Non Current-----------------14.0014.0014.0014.0014.00
Shareholder's Equity-95.3%15.003153072932922916.0023.0040.0022.0033.0025.0039.0051.0026.0021.0018.0018.0023.0021.0020.00
  Retained Earnings-1.6%-326-321-313-303-294-297-284-262-243-225-208-177-162-148-135-114-115-111-105-98.22-92.66
  Additional Paid-In Capital8.5%341315307293292291290285283247242202201199161135134130129119112
Shares Outstanding1270.5%19214.0013.009.009.009.009.009.009.008.007.006.00---------
Float------32.00---184---112---81.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations38.5%-6,800-11,048-10,052-3,9895,726-12,470-16,067-17,099-16,290-19,187-18,316-14,375-11,870-8,555-5,739-1,680-7,615-6,717-3,121-1,975-538
  Share Based Compensation6.7%9538938558437316685,3121,8921,7583,0741,4481,4371,4472,7861,116590819527597635945
Cashflow From Investing----133--39.00-56.00--11.00-81.00--21.00-391-63.0012,837-1,251-180-5.08-90.96-165-4991,391
Cashflow From Financing1688.5%10,69559813,74882.00--14,781-76.0047,64321,21837,8252001.0035,4859,0981363,51097.008,8176,1673,838
  Buy Backs-100.0%-3,640-------------------

AVTX Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues, net$ 236$ 14,949$ 1,353$ 17,155
Operating expenses:    
Cost of product sales2475281,5052,814
Research and development1,2497,04211,91725,136
Selling, general and administrative2,4903,2847,62417,752
Amortization expense00038
Total operating expenses3,98610,85421,04645,740
Total operating income (loss)(3,750)4,095(19,693)(28,585)
Other expense:    
Interest expense, net(1,553)(898)(3,498)(3,221)
Change in fair value of derivative liability1000(120)0
Other expense, net(17)0(42)(20)
Total other expense, net(1,470)(898)(3,660)(3,241)
(Loss) income before taxes(5,220)3,197(23,353)(31,826)
Income tax expense852320
Net (loss) income(5,228)3,192(23,376)(31,846)
Comprehensive loss$ (5,228)$ 3,192$ (23,376)$ (31,846)
Net (loss) income per share of common stock, basic (in dollars per share)$ (0.11)$ 0.34$ (0.96)$ (3.39)
Net (loss) income per share of common stock, diluted (in dollars per share)$ (0.11)$ 0.34$ (0.96)$ (3.39)
Product revenue, net    
Revenues:    
Total revenues, net$ 236$ 432$ 1,353$ 2,638
License revenue    
Revenues:    
Total revenues, net$ 0$ 14,517$ 0$ 14,517

AVTX Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 10,180$ 13,172
Other receivables1,5381,919
Inventory, net020
Prepaid expenses and other current assets9401,290
Restricted cash, current portion115
Total current assets12,65916,416
Property and equipment, net2,0712,411
Goodwill14,40914,409
Restricted cash, net of current portion131131
Total assets29,27033,367
Current liabilities:  
Accounts payable7892,882
Deferred revenue088
Accrued expenses and other current liabilities5,21613,214
Notes payable, current05,930
Total current liabilities6,00522,114
Notes payable, non-current013,486
Royalty obligation2,0002,000
Deferred tax liability, net164141
Derivative liability4,9504,830
Other long-term liabilities1,4561,711
Total liabilities14,57544,282
Stockholders’ equity (deficit):  
Common stock—$0.001 par value; 200,000,000 shares authorized at September 30, 2023 and December 31, 2022; 192,382,419 and 9,430,535 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively1929
Additional paid-in capital341,469292,900
Accumulated deficit(326,966)(303,824)
Total stockholders’ equity (deficit)14,695(10,915)
Total liabilities and stockholders’ equity (deficit)$ 29,270$ 33,367
AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEwww.avalotx.com
 EMPLOYEES20

Avalo Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Avalo Therapeutics, Inc.? What does AVTX stand for in stocks?

AVTX is the stock ticker symbol of Avalo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avalo Therapeutics, Inc. (AVTX)?

As of Wed Feb 28 2024, market cap of Avalo Therapeutics, Inc. is 854.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVTX stock?

You can check AVTX's fair value in chart for subscribers.

What is the fair value of AVTX stock?

You can check AVTX's fair value in chart for subscribers. The fair value of Avalo Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avalo Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avalo Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AVTX is over valued or under valued. Whether Avalo Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Avalo Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTX.

What is Avalo Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 28 2024, AVTX's PE ratio (Price to Earnings) is -25.74 and Price to Sales (PS) ratio is 51.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVTX PE ratio will change depending on the future growth rate expectations of investors.